Examinant per Autoria "Lluch, Ana"
Resultats per pàgina
Opcions d'ordenació
Ítem Accés Obert Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of spanish medical oncologists(Taylor & Francis, 2019) Sánchez-Rovira, Pedro; Zamora, Pilar; Salvador-Bofill, Javier; Morales, Serafín; Martínez-Jáñez, Noelia; Martínez-de-Dueñas, Eduardo; Lluch, Ana; Illarramendi, José Juan; Gómez-Pardo, Patricia; Gavilá Gregori, Joaquín; García-Palomo, Andrés; García-Mata, Jesús; Fernández, Yolanda; del Barco, Sonia; de Juan, Ana; Ciruelos, Eva; Chacón, José Ignacio; Calvo, Lourdes; Barnadas, Agustí; Albanell Mestres, Joan
Ítem Accés Obert Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval(Impact Journals, 2019) Ciruelos, Eva; Alba, Emilio; López, Rafael; Lluch, Ana; Martín, Miguel; Arroyo, Isabel; Navarro, Beatriz; Carcedo, David; Colomer, Ramon; Albanell Mestres, Joan
Ítem Accés Obert Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer(Impact Journals, 2014) Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico
Ítem Accés Obert Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis(Springer, 2022) Vazquez, Juan Carlos; Antolin, Silvia; Ruiz-Borrego, Manuel; Servitja Tormo, Sonia; Alba, Emilio; Barnadas, Agustí; Lluch, Ana; Martín, Miguel; Rodríguez-Lescure, Álvaro; Solà, Ivan; Bonfill, Xavier; Urrutia, Gerard; Sanchez-Rovira, Pedro
Ítem Accés Obert Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.(Oxford Open , 2015) Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelon, Lara, 1972-; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R.
Ítem Accés Obert FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth.(Nature Publishing Group, 2016) Slebe Concha, Juan Felipe, 1981-; Rojo, Federico; Vinaixa, Maria; García-Rocha, Mar; Testoni, Giorgia; Guiu, Marc; Planet, Evarist; Samino, Sara; Arenas, Enrique J.; Beltran Marqués, Antoni; Rovira Guerín, Ana; Lluch, Ana; Salvatella, Xavier; Yanes, Oscar; Albanell Mestres, Joan; Guinovart, Joan J. (Joan Josep), 1947-; Gomis, Roger R.
Ítem Accés Obert Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines(e-Century Publishing, 2017) Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico
Ítem Accés Obert MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma(Frontiers, 2020) Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar
Ítem Accés Obert miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer(MDPI, 2023) Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar
Ítem Accés Obert mTOR inhibition and T-DM1 in HER2-positive breast cancer(American Association for Cancer Research (AACR), 2022) Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan
Ítem Accés Obert Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma(Nature Research, 2016) Rojo, Federico; González-Pérez, Abel; Furriol, Jessica; Nicolau, Ma Jesús; Ferrer, Jaume; Burgués, Octavio; Sabbaghi Mehrjardi, Mohammad Ali; González Navarrete, Irene, 1983-; Cristóbal, Ion; Serrano, Laia; Zazo, Sandra; Madoz-Gúrpide, Juan; Servitja Tormo, Sonia; Tusquets, Ignasi; Albanell Mestres, Joan; Lluch, Ana; Rovira Guerín, Ana; Eroles, Pilar
Ítem Accés Obert Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.(Elsevier, 2016) Albanell Mestres, Joan; Svedman, Christer; Gligorov, Joseph; Holt, Simon D.H.; Bertelli, Gianfilippo; Blohmer, Jens-Uwe; Rouzier, Roman; Lluch, Ana; Eiermann, Wolfgang
Ítem Accés Obert PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.(Impact Journals, 2015) Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico
Ítem Accés Obert The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors(Nature Research, 2019) Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar
Ítem Accés Obert The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene(Nature Publishing Group, 2017) Tormo, Eduardo; Adam-Artigues, Anna; Ballester, Sandra; Pineda, Begoña; Zazo, Sandra; González-Alonso, Paula; Albanell Mestres, Joan; Rovira Guerín, Ana; Rojo, Federico; Lluch, Ana; Eroles, Pilar
Ítem Accés Obert Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial(Nature Research, 2014) Alba, Emilio; Albanell Mestres, Joan; Haba Rodríguez, Juan de la; Barnadas, Agustí; Calvo, Lourdes; Sánchez-Rovira, Pedro; Ramos, Manuel; Rojo, Federico; Burgués, Octavio; Carrasco, Eva María; Caballero, Rosalía; Porras, Ignacio; Tibau, Ariadna; Cámara, Maria del Carmen; Lluch, Ana